 SHANGHAI, Aug. 15, 2021 PRNewswire -- Arctic Vision, a China-based biotech company focused on innovative ophthalmic therapies, announced today the entering of an amendment to the exclusive license agreement with its partner Clearside Biomedical, Inc. Nasdaq: CLSD Clearside, to expand the licensed territory for ARVN001 triamcinolone acetonide suprachoroidal injectable suspension, known as XIPERETM in the U.S. from Greater China mainland China, Hong Kong, Macau and Taiwan and South Korea to also include ASEAN Countries Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, Singapore, Thailand, and Vietnam and India . ARVN001 is a proprietary suspension of the corticosteroid triamcinolone acetonide formulated for administration to the suprachoroidal space SCS through Clearsides patented SCS Microinjector. 